Scholarlink

<p>Alzheimer’s disease (AD) progression involves complex molecular mechanisms underlying neuronal dysfunction. While emerging evidence on long noncoding RNAs (lncRNAs) is accumulating, the relevance of nuclear noncoding RNAs (ncRNAs) to neurodegenerative diseases remains poorly understood. Small Cajal body-specific RNA 13 (<i>scaRNA13</i>) is a nuclear ncRNA implicated in RNA species regulation, which remains insufficiently characterized in neuronal systems and AD pathogenesis. Here, we performed integrative analyses of human postmortem brain transcriptomes and AD mouse models to examine <i>scaRNA13</i> expression across disease stages, sex, and brain regions. RNA-seq and proteomic analyses were used to assess <i>scaRNA13</i>-associated changes in gene expression, splicing, and RNA-protein interactions. Functional assays in neuronal cells were conducted to evaluate the effects of <i>scaRNA13</i> perturbation on RNA processing, protein synthesis, and tau-related pathology. <i>scaRNA13</i> was aberrantly upregulated in AD patient brains with a pronounced elevation observed in female patients at advanced stages. Perturbation of <i>scaRNA13</i> altered splicing patterns and global translational capacity, accompanied by altered tau aggregation- and phosphorylation-related phenotypes in neuronal cell systems. These findings support <i>scaRNA13</i> as an AD-associated nuclear ncRNA candidate and suggest that <i>scaRNA13</i> perturbation is associated with changes in RNA processing, translational regulation, and tau-related cellular phenotypes in neuronal cell systems.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative multi-omics analyses reveal nuclear noncoding RNA-mediated regulatory landscape in Alzheimer’s disease

  • 期刊论文

  • 发表日期：

    2026年7月11日

查看全文
  • Sumin Yang,
  • Sung-Hyun Kim,
  • Jeonghyeon Choi,
  • Yeyoung Lee,
  • Jeehye Jung,
  • Jae-Yeol Joo

摘要

Alzheimer’s disease (AD) progression involves complex molecular mechanisms underlying neuronal dysfunction. While emerging evidence on long noncoding RNAs (lncRNAs) is accumulating, the relevance of nuclear noncoding RNAs (ncRNAs) to neurodegenerative diseases remains poorly understood. Small Cajal body-specific RNA 13 (scaRNA13) is a nuclear ncRNA implicated in RNA species regulation, which remains insufficiently characterized in neuronal systems and AD pathogenesis. Here, we performed integrative analyses of human postmortem brain transcriptomes and AD mouse models to examine scaRNA13 expression across disease stages, sex, and brain regions. RNA-seq and proteomic analyses were used to assess scaRNA13-associated changes in gene expression, splicing, and RNA-protein interactions. Functional assays in neuronal cells were conducted to evaluate the effects of scaRNA13 perturbation on RNA processing, protein synthesis, and tau-related pathology. scaRNA13 was aberrantly upregulated in AD patient brains with a pronounced elevation observed in female patients at advanced stages. Perturbation of scaRNA13 altered splicing patterns and global translational capacity, accompanied by altered tau aggregation- and phosphorylation-related phenotypes in neuronal cell systems. These findings support scaRNA13 as an AD-associated nuclear ncRNA candidate and suggest that scaRNA13 perturbation is associated with changes in RNA processing, translational regulation, and tau-related cellular phenotypes in neuronal cell systems.